| Dear Friend: We are pleased to provide you with the April 2005 edition of the MMRC Update. This monthly briefing was created to keep you informed of the MMRC's progress toward its ultimate goal of accelerating drug development and improving patient outcomes. We hope you find this newsletter informative and we welcome any feedback you may have. For more information, contact us at info@themmrc.org. Thank you for your support of the MMRC. |
The MMRC is pleased to announce the launch of the Validation Core. Led by Leif Bergsagel, MD, Mayo Clinic, the Validation Core will focus on the identification and validation of new and existing targets for myeloma and new and combination therapies active against these targets. To advance these efforts, the Validation Core has created an extensively characterized panel of myeloma cell lines that will form the basis for future target validation and drug validation studies. "The creation and maintenance of high quality myeloma cells lines will serve as an invaluable resource for our industry partners as they pursue drug screening projects," said Dr. Bergsagel.
The MMRC's president and founder will be a featured speaker at the 2005 Annual Milken Institute Global Conference. In its 8th year, this conference brings together key opinion leaders from a broad range of disciplines to discuss some of the today's most pressing issues - including medical research and drug development. The MMRC was invited to present its innovative research model for rapid drug development in myeloma.
The MMRC, MMRC Member Institutions, and industry partners have successfully developed uniform contracts and other template documents for use in MMRC research efforts. These boilerplate templates-including Informed Consent Forms (ICF), Clinical Trials Agreements (CTA), and Case Report Forms (CRF) will significantly streamline business and clinical research processes by providing pre-defined terms and language that eliminates the need to negotiate or revise documents for each new research project.
